Drugs / Daratumumab and Hyaluronidase-fihj
Daratumumab and Hyaluronidase-fihj
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06022939 Background | Jul 2024 → Jul 2030 expected | AL amyloidosis | SWOG Cancer Research Network | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Daratumumab and Hyaluronidase-fihj | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06022939 ↗ |
| Action | Inhibit | “Daratumumab may block CD38” NCT06022939 ↗ |
| Modality | Monoclonal antibody | “Daratumumab is in a class of medications called monoclonal antibodies.” NCT06022939 ↗ |
| Route | Subcutaneous | “Given SC” NCT06022939 ↗ |